Literature DB >> 17137644

Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.

Mariana Baz1, Yacine Abed, Guy Boivin.   

Abstract

There is a limited information with regard to the neuraminidase (NA) mutations conferring resistance to peramivir and zanamivir in the influenza N1 background. In this study, an influenza A/WSN/33 (H1N1) recombinant virus was passaged under peramivir or zanamivir pressure. The peramivir-selected variant had a H274Y mutation in the neuraminidase (NA) gene conferring resistance to peramivir and oseltamivir but susceptibility to zanamivir. The zanamivir-selected variant had a massive deletion in the region encoding the NA active center and an A200T hemagglutinin mutation. This variant exhibited reduced susceptibility to zanamivir with a drug-dependent phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17137644     DOI: 10.1016/j.antiviral.2006.10.012

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  30 in total

1.  Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.

Authors:  Yacine Abed; Andrés Pizzorno; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

Authors:  Andrés Pizzorno; Xavier Bouhy; Yacine Abed; Guy Boivin
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase.

Authors:  Nicole M Bouvier; Saad Rahmat; Natalie Pica
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

4.  Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.

Authors:  Gallen B Triana-Baltzer; Rebecca L Sanders; Maria Hedlund; Kellie A Jensen; Laura M Aschenbrenner; Jeffrey L Larson; Fang Fang
Journal:  J Antimicrob Chemother       Date:  2010-11-21       Impact factor: 5.790

5.  Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.

Authors:  Mélanie Samson; Yacine Abed; François-Marc Desrochers; Stephanie Hamilton; Angela Luttick; Simon P Tucker; Melinda J Pryor; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

6.  Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.

Authors:  Matthew J Memoli; Rachel J Hrabal; Arash Hassantoufighi; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  Clin Infect Dis       Date:  2010-05-01       Impact factor: 9.079

7.  Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics.

Authors:  George K Siberry; Mark J Abzug; Sharon Nachman; Michael T Brady; Kenneth L Dominguez; Edward Handelsman; Lynne M Mofenson; Steve Nesheim
Journal:  Pediatr Infect Dis J       Date:  2013-11       Impact factor: 2.129

8.  In Vitro Evaluation of Absorption Characteristics of Peramivir for Oral Delivery.

Authors:  Ying Li; Zhiyuan Wang; Xin Li; Wei Gong; Xiangyang Xie; Yang Yang; Wu Zhong; Aiping Zheng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

9.  Virus susceptibility analyses from a phase IV clinical trial of inhaled zanamivir treatment in children infected with influenza.

Authors:  Phillip J Yates; Nalini Mehta; Joseph Horton; Margaret Tisdale
Journal:  Antimicrob Agents Chemother       Date:  2013-01-18       Impact factor: 5.191

10.  Impact of calcium on N1 influenza neuraminidase dynamics and binding free energy.

Authors:  Morgan Lawrenz; Jeff Wereszczynski; Rommie Amaro; Ross Walker; Adrian Roitberg; J Andrew McCammon
Journal:  Proteins       Date:  2010-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.